Search results
Showing 16 to 30 of 687 results for must
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.
Show all sections
Care and support of people growing older with learning disabilities (NG96)
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.
Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA1109Show all sections
Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
Evidence-based recommendations on guselkumab (Tremfya) for previously treated moderately to severely active Crohn's disease.
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Evidence-based recommendations on mirikizumab (Omvoh) for previously treated moderately to severely active Crohn's disease in adults.
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)
Evidence-based recommendations on zanubrutinib for treating relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only.